

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



李氏大藥廠

## Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司\*

(incorporated in the Cayman Islands with limited liability)

(Stock code: 950)

### GRANT OF SHARE OPTIONS

The Board announces that on 25 April 2022, the Company has granted Options to subscribe for a total of 1,176,000 Shares under the Share Option Scheme.

This announcement is made pursuant to rule 17.06A of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited.

The board of directors (the “**Board**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”) announces that on 25 April 2022, the Company has granted share options (the “**Options**”) to subscribe for a total of 1,176,000 ordinary shares of the Company (the “**Shares**”) under the share option scheme adopted on 10 May 2012 (the “**Share Option Scheme**”). The following are the details of the grant of Options:

Date of grant	25 April 2022
Exercise price of the Options	HK\$2.076 per Share
Number of Options granted	1,176,000 Shares
Closing price of the Shares on the date of grant	HK\$1.980 per Share
Average closing price of the Shares for the five business days immediately preceding the date of grant	HK\$2.076 per Share
Validity period of the Options	(i) the first 50% of the Options is exercisable from 25 October 2022, being six months from the date of grant of the Options, to 24 April 2032 (both days inclusive); and  (ii) the remaining 50% of the Options is exercisable from 25 July 2023, being fifteen months from the date of grant of the Options, to 24 April 2032 (both days inclusive).

Among the aforesaid Options granted, Options in respect of a total of 1,176,000 Shares were granted to the directors of the Company as follows:

<u>Name</u>	<u>Position</u>	<u>Number of Options</u>
Lee Siu Fong	Chairman	588,000
Leelalertsuphakun Wanee	Managing Director	588,000
Total		1,176,000

The granting of the share options to the directors of the Company were approved by the independent non-executive directors of the Company.

By order of the Board  
**Lee's Pharmaceutical Holdings Limited**  
**Lee Siu Fong**  
*Chairman*

Hong Kong, 25 April 2022

*\* For identification purpose only*

*As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive directors of the Company, Dr. Li Xiaoyi and Mr. James Charles Gale are non-executive directors of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.*